-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2024-510656-13-00
5
2022-11-08
Migraine
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2024-511635-94-00
4
2022-07-11
Relapsed or Refractory Plasmablastic lymphoma
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-515063-66-00
4
2021-03-30
Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2024-517864-49-01
5
2020-09-08
Autosomal Dominant Polycystic Kidney Disease
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-518901-16-00
4
2019-07-29
RIS (Radiologically Isolated Syndrome)
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-518940-19-02
4
2025-01-28
Acute Myeloid Leukemia (AML)
-
2024-518669-83-00
4
2024-12-05
acute promyelocytic leukemia (APL) in children and adolescents
-
2024-512676-36-00
10
2024-10-09
Langerhans Cell Histiocytosis
-
2023-507851-31-00
5
2024-09-23
Immunoglobulin A Nephropathy (IgAN)
-
2024-513271-41-00
4
2024-09-16
colorectal metastatic cancer
-
2024-512747-23-00
5
2024-07-30
Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2023-509026-21-00
6
2024-06-03
severe asthma
-
2022-502518-98-00
5
2024-04-26
nonsegmental vitiligo
-
2024-512745-16-00
5
2022-04-13
Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2023-510241-16-00
4
2021-12-03
Acute Myeloid Leukemia secondary to myeloproliferative neoplasms